Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GLGC Gene Logic -- Ignore unavailable to you. Want to Upgrade?

To: Steve Lokness who wrote (268)	2/6/2007 1:27:38 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 360

The enterprise value of Gene Logic is up to a whopping $7m says Yahoo. I think it is actually zero guessing that cash is around $55m--but we will see what the cash balance is soon enough. fwiw, I assume that the Gene Logic Xenogen license is good til three years from November 17, 2004-- but you might want to look at the glgc annual report and scrutinize that. I'll try to remember to do a ctrl-F and search for xenogen or caliper when the next annual report is out in the spring.

To: Steve Lokness who wrote (268)	6/20/2007 12:53:30 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 360

I had forgotten to do that ^F, here is the text from the annual report regarding the xenogen license Drug Repositioning Division In our Drug Repositioning Division, we have a non-exclusive license and sublicense from Promega Corporation (the “Promega License”) to use the luminescence technology we use in our real-time in vivo imaging. The term of the agreement is for the life of the relevant patents, unless earlier terminated upon breach by either party, bankruptcy or termination of Promega’s rights by an academic institution that holds certain rights to a portion of the technology (in which case we would seek separate licenses from Promega for its technology and directly from the institution). Under the terms of the agreement, we paid Promega an initial fee and we pay Promega an annual license maintenance fee and royalties on luminescent assay reagents we use that are not purchased from Promega. We also have a non-exclusive license with Xenogen Corporation (the “Xenogen License”), for which we pay an annual license fee to use the Xenogen Imaging Technology and certain related software in connection with our use of certain imaging equipment we purchased from Xenogen for use in performing real-time in vivo imaging. The term of the Xenogen license ends in 2008, with a three year renewal option, subject to earlier termination if we fail to make timely payment or otherwise breach the terms of the agreement, and we have agreed to indemnify Xenogen and certain other persons and entities for liability resulting from our use of the technology.